Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Wilms Tumor 1Multiple Myeloma 1

Interventions

X-Rays 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Phantoms, Imaging 5Vincristine 4Nuclear Medicine Department, Hospital 4Doxorubicin 4Dactinomycin 4Radiotherapy 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2Vemurafenib 2Radiotherapy, Conformal 2Radiation 2LY3023414 2Etoposide 2Cyclophosphamide 2Carboplatin 2thymoglobulin 1sargramostim 1pembrolizumab 1lorvotuzumab mertansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Wilms Tumor × Immunomodulating Agents × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡